BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 26910108)

  • 1. Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients.
    Nagata E; Ogino M; Iwamoto K; Kitagawa Y; Iwasaki Y; Yoshii F; Ikeda JE;
    PLoS One; 2016; 11(2):e0149509. PubMed ID: 26910108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
    Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
    Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    Aggarwal SP; Zinman L; Simpson E; McKinley J; Jackson KE; Pinto H; Kaufman P; Conwit RA; Schoenfeld D; Shefner J; Cudkowicz M;
    Lancet Neurol; 2010 May; 9(5):481-8. PubMed ID: 20363190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
    Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
    J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial.
    Mora JS; Genge A; Chio A; Estol CJ; Chaverri D; Hernández M; Marín S; Mascias J; Rodriguez GE; Povedano M; Paipa A; Dominguez R; Gamez J; Salvado M; Lunetta C; Ballario C; Riva N; Mandrioli J; Moussy A; Kinet JP; Auclair C; Dubreuil P; Arnold V; Mansfield CD; Hermine O;
    Amyotroph Lateral Scler Frontotemporal Degener; 2020 Feb; 21(1-2):5-14. PubMed ID: 31280619
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial.
    Lombardo FL; Spila Alegiani S; Mayer F; Cipriani M; Lo Giudice M; Ludolph AC; McDermott CJ; Corcia P; Van Damme P; Van den Berg LH; Hardiman O; Nicolini G; Vanacore N; Dickie B; Albanese A; Puopolo M;
    Trials; 2023 Dec; 24(1):792. PubMed ID: 38053196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis.
    Tanaka K; Kanno T; Yanagisawa Y; Yasutake K; Hadano S; Yoshii F; Ikeda JE
    Exp Neurol; 2011 Nov; 232(1):41-52. PubMed ID: 21867702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.
    Bensimon G; Lacomblez L; Meininger V
    N Engl J Med; 1994 Mar; 330(9):585-91. PubMed ID: 8302340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results.
    Saccà F; Quarantelli M; Rinaldi C; Tucci T; Piro R; Perrotta G; Carotenuto B; Marsili A; Palma V; De Michele G; Brunetti A; Brescia Morra V; Filla A; Salvatore M
    J Neurol; 2012 Jan; 259(1):132-8. PubMed ID: 21706151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
    Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
    Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis.
    Elia AE; Lalli S; Monsurrò MR; Sagnelli A; Taiello AC; Reggiori B; La Bella V; Tedeschi G; Albanese A
    Eur J Neurol; 2016 Jan; 23(1):45-52. PubMed ID: 25664595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial.
    Kim S; Kim JK; Son MJ; Kim D; Song B; Son I; Kang HW; Lee J; Kim S
    Trials; 2018 Apr; 19(1):225. PubMed ID: 29653550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.
    Beghi E; Pupillo E; Bonito V; Buzzi P; Caponnetto C; Chiò A; Corbo M; Giannini F; Inghilleri M; Bella VL; Logroscino G; Lorusso L; Lunetta C; Mazzini L; Messina P; Mora G; Perini M; Quadrelli ML; Silani V; Simone IL; Tremolizzo L;
    Amyotroph Lateral Scler Frontotemporal Degener; 2013 Sep; 14(5-6):397-405. PubMed ID: 23421600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.
    Lacomblez L; Bensimon G; Leigh PN; Guillet P; Meininger V
    Lancet; 1996 May; 347(9013):1425-31. PubMed ID: 8676624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Nanocurcumin as Add-On Therapy to Riluzole in Patients With Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial.
    Ahmadi M; Agah E; Nafissi S; Jaafari MR; Harirchian MH; Sarraf P; Faghihi-Kashani S; Hosseini SJ; Ghoreishi A; Aghamollaii V; Hosseini M; Tafakhori A
    Neurotherapeutics; 2018 Apr; 15(2):430-438. PubMed ID: 29352425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31].
    Al-Chalabi A; Shaw PJ; Young CA; Morrison KE; Murphy C; Thornhill M; Kelly J; Steen IN; Leigh PN;
    BMC Neurol; 2011 Sep; 11():111. PubMed ID: 21936930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study protocol of RESCUE-ALS: A Phase 2,
    Vucic S; Kiernan MC; Menon P; Huynh W; Rynders A; Ho KS; Glanzman R; Hotchkin MT
    BMJ Open; 2021 Jan; 11(1):e041479. PubMed ID: 33431491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.